Learn More
Description
A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75kDa subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined. [provided by RefSeq
Specifications
Specifications
| Antigen | RFX5 |
| Applications | Western Blot |
| Classification | Polyclonal |
| Concentration | 0.5 mg/mL |
| Conjugate | Unconjugated |
| Description | Goat polyclonal antibody raised against synthetic peptide of RFX5. |
| Dilution | ELISA (1:1000) Western Blot (1-3ug/ml) The optimal working dilution should be determined by the end user. |
| Formulation | In Tris saline, pH 7.3 (0.02% sodium azide, 0.5% BSA) |
| Gene | RFX5 |
| Gene Symbols | RFX5 |
| Show More |
For Research Use Only
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.